

February 1, 2018

Sumitomo Dainippon Pharma Co., Ltd.

**Sumitomo Dainippon Pharma Announces an Atypical Antipsychotic  
LONASEN® is Now Available in China**

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Masayo Tada) announced today that Sumitomo Pharmaceuticals (Suzhou) Co., Ltd., its wholly-owned subsidiary in China, launches an atypical antipsychotic LONASEN® (generic name: blonanserin) in China on February 1, 2018.

LONASEN® is an atypical antipsychotic agent discovered by Sumitomo Dainippon Pharma and is marketed by the company in Japan since April 2008 for the treatment of schizophrenia. As announced on February 28, 2017, China Food and Drug Administration (CFDA) granted the import drug license in China for LONASEN® in February 2017.

Sumitomo Dainippon Pharma expects to make a contribution to the treatment of patients with schizophrenia in China by launching LONASEN® as a new treatment option in China.

(Reference)

**About LONASEN®**

LONASEN® is an atypical antipsychotic agent with novel structure, discovered by Sumitomo Dainippon Pharma. This drug blocks dopamine D<sub>2</sub> receptors and serotonin 5-HT<sub>2A</sub> receptors. In clinical studies, this drug showed efficacy for not only positive symptoms of schizophrenia (such as hallucinations or delusions), but also negative symptoms (such as flat affect or hypobulia). In Japan it is available from Sumitomo Dainippon Pharma since April 2008 for the treatment of schizophrenia.

Contact:

Public Relations/Investor Relations

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407(Osaka)

+81-3-5159-3300 (Tokyo)